gdc

Newsworthy

Lynparza Approved as Maintenance Treatment for Ovarian Cancer
FDA NewsNewsworthyOvarian Cancer
In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
Neratinib First Long-Term Adjuvant Therapy for Early-Stage, HER2-Positive Breast Cancer
Breast CancerFDA NewsNewsworthy
On July 17, 2017, the FDA approved Nerlynx (neratinib; from Puma Biotechnology) for long-term adjuvant treatment of early-stage, HER2-positive breast cancer in patients who received previous therapy with Herceptin (trastuzumab).
Gene Therapy a New Milestone in Immunotherapy
ImmunotherapyNewsworthy
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer.
CancerCare® Expands Financial Assistance for Cancer Patients Affected by Hurricanes
Newsworthy
As part of its mission to provide help and hope to anyone affected by a cancer diagnosis, CancerCare® is offering direct financial assistance to cancer patients residing in the United States, including Puerto Rico and the U.S. Virgin Islands, who have been impacted by Hurricanes Harvey, Irma, Jose or Maria.
Tecentriq Now Approved as First Treatment for Advanced Bladder Cancer in Some Patients
FDA NewsNewsworthy
On April 17, 2017, the FDA approved the PD-L1 inhibitor Tecentriq (atezolizumab; from Genentech) for use as first-line treatment for patients with locally advanced or metastatic urothelial carcinoma who cannot use cisplatin chemotherapy.
Page 2 of 4
Results 11 - 20 of 35

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Need multiple copies? Click here